NorthCoast Asset Management LLC reduced its stake in shares of Sanofi SA (NYSE:SNY) by 2.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,908 shares of the company’s stock after selling 1,755 shares during the quarter. NorthCoast Asset Management LLC’s holdings in Sanofi were worth $2,637,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Huntington National Bank boosted its stake in Sanofi by 24.9% in the second quarter. Huntington National Bank now owns 6,037 shares of the company’s stock valued at $242,000 after acquiring an additional 1,202 shares during the last quarter. Advisor Partners LLC boosted its stake in Sanofi by 23.7% in the second quarter. Advisor Partners LLC now owns 6,503 shares of the company’s stock valued at $260,000 after acquiring an additional 1,245 shares during the last quarter. Pekin Singer Strauss Asset Management IL boosted its stake in Sanofi by 3.6% in the second quarter. Pekin Singer Strauss Asset Management IL now owns 38,355 shares of the company’s stock valued at $1,535,000 after acquiring an additional 1,315 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its stake in Sanofi by 8.3% in the second quarter. Steward Partners Investment Advisory LLC now owns 18,344 shares of the company’s stock valued at $734,000 after acquiring an additional 1,401 shares during the last quarter. Finally, Zions Bancorporation boosted its stake in Sanofi by 8.7% in the second quarter. Zions Bancorporation now owns 19,340 shares of the company’s stock valued at $774,000 after acquiring an additional 1,544 shares during the last quarter. 7.54% of the stock is currently owned by institutional investors and hedge funds.

SNY opened at $43.75 on Tuesday. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $109.88 billion, a price-to-earnings ratio of 13.98, a PEG ratio of 2.35 and a beta of 0.85. Sanofi SA has a twelve month low of $37.43 and a twelve month high of $50.65.

Sanofi (NYSE:SNY) last posted its earnings results on Tuesday, July 31st. The company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.02. The company had revenue of $8.18 billion for the quarter, compared to analyst estimates of $8.27 billion. Sanofi had a net margin of 10.29% and a return on equity of 23.77%. The business’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period last year, the business posted $1.35 earnings per share. research analysts predict that Sanofi SA will post 3.14 earnings per share for the current year.

A number of equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Tuesday, August 28th. BNP Paribas raised shares of Sanofi from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 1st. Deutsche Bank reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, August 1st. Argus raised their price objective on shares of Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, August 24th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Tuesday, July 31st. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $49.00.

In other Sanofi news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.00% of the company’s stock.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Trading Strategy Methods and Types

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.